number of weight loss drug prescriptions q3 2024 semaglutide tirzepatide data LLY Q3 Performance Review: Results Exceed Expectations, Tirzepatide Becomes Top-Selling Drug Tirzepatide Dosing Chart 2026: 2.5-15
Description
Ozempic is FDA-approved for type 2 diabetes and to reduce the risk of kidney disease progression and cardiovascular death in adults with type 2 diabetes, and as of January 2025, for chronic kidney disease
Trajenta (Linagliptin/Metformin) Trajenta 2022 sales: $1.846 billion Company/Developer: Boehringer Ingelheim and Eli Lilly Date of first FDA approval: May 2, 2021 Indications Trajenta is FDA-approved for: Trajenta serves as a DPP-4 inhibitor, prescribed as a supplementary measure alongside diet and exercise to enhance glycemic control in adults diagnosed with type 2 diabetes mellitus
What this means for oral drops users Users reviewing oral tirzepatide drops should understand that the products they are evaluating exist in a regulatory grey area
Some people find that B12-enhanced semaglutide causes fewer energy crashes
If choosing drops, optimize your technique Users who get the best results from oral drops consistently emphasize proper technique
What the clinical trials show The SURMOUNT clinical trial program is the largest body of evidence supporting tirzepatide for weight loss
